Evidence map›Paper›PMID 31385982›Full record

ArticleNeuro-oncology practice2017

Impact of standard care on elderly glioblastoma patients.

Sarah Lapointe, Marie Florescu, David Simonyan, Karine Michaud

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarah LapointeNeurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (S.L.); Hematology and Oncology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (M.F.); Neurosurgery Division, CHU Enfant-Jésus Hospital, Laval University, 1401 18th street, Québec G1J1Z4, Canada (K.M.); Clinical and Evaluative Research Platform, CHU de Québec Research Center, 10 de l'Espinay, D6-747, Québec, QC, G1L 3L5, Canada (D.S.).
Marie FlorescuNeurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (S.L.); Hematology and Oncology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (M.F.); Neurosurgery Division, CHU Enfant-Jésus Hospital, Laval University, 1401 18th street, Québec G1J1Z4, Canada (K.M.); Clinical and Evaluative Research Platform, CHU de Québec Research Center, 10 de l'Espinay, D6-747, Québec, QC, G1L 3L5, Canada (D.S.).
David SimonyanNeurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (S.L.); Hematology and Oncology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (M.F.); Neurosurgery Division, CHU Enfant-Jésus Hospital, Laval University, 1401 18th street, Québec G1J1Z4, Canada (K.M.); Clinical and Evaluative Research Platform, CHU de Québec Research Center, 10 de l'Espinay, D6-747, Québec, QC, G1L 3L5, Canada (D.S.).
Karine MichaudNeurology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (S.L.); Hematology and Oncology Division, CHUM Notre-Dame Hospital, University of Montreal, 1560 Sherbrooke East, Montreal H2L 4M1, Canada (M.F.); Neurosurgery Division, CHU Enfant-Jésus Hospital, Laval University, 1401 18th street, Québec G1J1Z4, Canada (K.M.); Clinical and Evaluative Research Platform, CHU de Québec Research Center, 10 de l'Espinay, D6-747, Québec, QC, G1L 3L5, Canada (D.S.).
Université de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUncertainty persists about the survival advantage of concomitant and adjuvant temozolomide (TMZ) plus radiotherapy (RT) in elderly patients with newly diagnosed glioblastoma (GBM). We compared the clinical outcome of unselected elderly GBM patients treated with 4 adjuvant treatment modalities, including the

methodsFrom 2010 to 2014, retrospective chart review was performed on 171 GBM patients aged ≥55 who received either concurrent chemoradiation therapy (CCRT) with standard 60 Gy/30 (SRT); CCRT with hypofractionated 40 Gy/15 (HRT); HRT alone; or TMZ alone. Stratification is by age (55-69, ≥70), KPS (<70, ≥70), and resection status (biopsy, resection).

resultsOut of 171 patients identified, 128(75%) had surgical resection, median age was 66(55-83), and median overall survival (mOS) 11.4mo. Majority (109/171) were treated according to the

conclusionsOur data suggests that, despite having a worse global prognostic than their younger counterparts, GBM patients ≥70yo with a good performance status could be treated according to the

Indexed as

elderlyglioblastomaradiotherapytemozolomidetreatment

Identifiers

PMID31385982
PMCPMC6655425
OpenAlexW2418309668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.